Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
36 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Bionor Pharma ASA - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Bionor Pharma ASA - Product Pipeline Review - 2014', provides an overview of the Bionor Pharma ASA's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Bionor Pharma ASA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Bionor Pharma ASA including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Bionor Pharma ASA's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Bionor Pharma ASA's pipeline products Reasons to buy - Evaluate Bionor Pharma ASA's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Bionor Pharma ASA in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Bionor Pharma ASA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Bionor Pharma ASA and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Bionor Pharma ASA - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Bionor Pharma ASA and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Bionor Pharma ASA Snapshot 5 Bionor Pharma ASA Overview 5 Key Information 5 Key Facts 5 Bionor Pharma ASA - Research and Development Overview 6 Key Therapeutic Areas 6 Bionor Pharma ASA - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Combination Treatment Modalities 10 Bionor Pharma ASA - Pipeline Products Glance 11 Bionor Pharma ASA - Clinical Stage Pipeline Products 11 Phase II Products/Combination Treatment Modalities 11 Phase I Products/Combination Treatment Modalities 12 Bionor Pharma ASA - Early Stage Pipeline Products 13 Preclinical Products/Combination Treatment Modalities 13 Discovery Products/Combination Treatment Modalities 14 Bionor Pharma ASA - Drug Profiles 15 Vacc-4x 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 Vacc-C5 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Vacc-4x + Vacc-C5 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Vacc-Flu 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Vacc-HCV 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Vacc-CMV 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Vacc-HPV 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Bionor Pharma ASA - Pipeline Analysis 25 Bionor Pharma ASA - Pipeline Products by Target 25 Bionor Pharma ASA - Pipeline Products by Route of Administration 26 Bionor Pharma ASA - Pipeline Products by Molecule Type 27 Bionor Pharma ASA - Recent Pipeline Updates 28 Bionor Pharma ASA - Company Statement 33 Bionor Pharma ASA - Locations And Subsidiaries 34 Head Office 34 Other Locations & Subsidiaries 34 Appendix 35 Methodology 35 Coverage 35 Secondary Research 35 Primary Research 35 Expert Panel Validation 35 Contact Us 36 Disclaimer 36
List of Tables Bionor Pharma ASA, Key Information 5 Bionor Pharma ASA, Key Facts 5 Bionor Pharma ASA - Pipeline by Indication, 2014 7 Bionor Pharma ASA - Pipeline by Stage of Development, 2014 8 Bionor Pharma ASA - Monotherapy Products in Pipeline, 2014 9 Bionor Pharma ASA - Combination Treatment Modalities in Pipeline, 2014 10 Bionor Pharma ASA - Phase II, 2014 11 Bionor Pharma ASA - Phase I, 2014 12 Bionor Pharma ASA - Preclinical, 2014 13 Bionor Pharma ASA - Discovery, 2014 14 Bionor Pharma ASA - Pipeline by Target, 2014 25 Bionor Pharma ASA - Pipeline by Route of Administration, 2014 26 Bionor Pharma ASA - Pipeline by Molecule Type, 2014 27 Bionor Pharma ASA - Recent Pipeline Updates, 2014 28 Bionor Pharma ASA, Subsidiaries 34
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.